In Brazil, Mexico and Argentina, High Out-of-Pocket Costs For DPP-IV Inhibitors and GLP-1 Analogues Greatly Limit Prescribing of These Drugs in the Public Setting for the Treatment of Type 2 Diabetes

However, Patient Access to Premium-Priced Type 2 Diabetes Agents is Improving and Developers of Noninsulin Therapies Must Optimize This Opportunity, According to a New Report From Decision Resources

Jul 02, 2013, 10:00 ET from Decision Resources

BURLINGTON, Mass., July 2, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that premium-priced DPP-IV inhibitors and GLP-1 analogues lack nationwide government coverage in Brazil, Mexico and Argentina. Government-sponsored diabetes programs and most Social Funds (Obras Sociales) do not provide any coverage/reimbursement to these agents in Argentina. In Mexico, approximately half of the type 2 diabetes population lack coverage for these agents, and the remaining population has access only to one agent from each class through Social Security. In Brazil, public coverage from the Unified Health System's (Sistema Unico de Saude) programs for pharmaceutical assistance is non-existent and, as a result, surveyed clinicians report low patient shares in the public setting. Out-of-pocket costs feature prominently as the top factor limiting prescribing of these drugs, especially GLP-1 analogues, which can cost more than twice as much per day as DPP-IV inhibitors. Patient shares among private patients are higher for both drug classes.


The Emerging Markets Physician & Payer Forum report entitled The Market Landscape for Type 2 Diabetes in Latin America: Physician and Payer Insights on Access Levers and Barriers for Current and Emerging Noninsulin Antidiabetic Agents also finds that the perception that the current therapeutic arsenal is already adequate is the greatest obstacle to access to newer and improved therapies for type 2 diabetes. Decision Resources expects that it will take powerful pharmacoeconomic data demonstrating a clear cost-benefit over current therapies to overcome this obstacle.  

The findings also reveal that a majority of surveyed physician in Mexico and Argentina are unaware of the SGLT-2 inhibitor drug class. Therefore, as the type 2 diabetes market expands and becomes increasingly crowded, marketers of novel emerging agents must educate clinicians to optimize uptake.

"Payers in all countries identify a need for the negotiation of discount protocols between manufacturers and hospital/government programs in order for new drugs to be accessible to institutions' budgets," said Decision Resources Analyst Andreia Ribeiro, Ph.D. "For example, some payers indicate that securing a supply of free samples in reference and university hospitals develops brand loyalty among physicians that would be transferred within practice settings. Others remind us that patient groups are key to generating momentum toward increased disease awareness and rights to healthcare. Investing in individualized strategies targeting each of these stakeholders will ultimately lead to advantaged drug positioning towards inclusion in the therapeutic formularies."

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources